<- Go Home
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Market Cap
$151.5M
Volume
202.9K
Cash and Equivalents
$46.0M
EBITDA
-$65.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$233.0K
Profit Margin
100.00%
52 Week High
$3.82
52 Week Low
$1.23
Dividend
N/A
Price / Book Value
3.94
Price / Earnings
-2.32
Price / Tangible Book Value
3.95
Enterprise Value
$106.1M
Enterprise Value / EBITDA
-1.63
Operating Income
-$66.2M
Return on Equity
102.94%
Return on Assets
-54.20
Cash and Short Term Investments
$46.0M
Debt
$693.0K
Equity
$42.6M
Revenue
$233.0K
Unlevered FCF
-$34.1M
Sector
Biotechnology
Category
N/A